Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that ...

Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...

Electronic signature service Docusign beat expectations with a strong fourth-quarter earnings report, driven by its new artificial intelligence-powered platform.

U.S. equities took off at midday as it appeared Democrats in the Senate would join Republicans in approving a spending plan ...

1 Day MS 2.66% DJIA 0.94% S&P 500 1.29% Financial Services -1.24% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

Preformed Line Products Company today reported financial results for its fourth quarter of 2024 and full year ended December 31, ...

His stated philosophy revolves around a stock’s moat, management, price, and whether he feels he has an informational edge versus the street. Like current manager Joe Fath, he’ll focus on fast ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In June 2023, it launched T. Rowe Price Capital Appreciation Equity, an actively managed stock-only ETF, and in November 2023, it launched T. Rowe Price Capital Appreciation and Income ...

Bank of America Corporation, through its subsidiaries, provides various financial products and services for individual consumers, small and middle-market businesses, institutional investors, large ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.